Domo signs strategic collaboration agreement with AWS for AI solutions
Immix Biopharma , Inc. (NASDAQ:IMMX), Chief Financial Officer Gabriel Morris, recently purchased 2,225 shares of common stock at a price of $2.279 per share, for a total transaction value of $5070. The transaction occurred on June 18, 2025. The stock, currently trading at $2.40, has shown strong momentum with a 24% gain over the past year. According to InvestingPro analysis, the company maintains a FAIR financial health score despite rapid cash burn.
Following this transaction, Morris directly owns 288,059 shares of Immix Biopharma, Inc. It should be noted that Morris also indirectly owns 270,844 shares through Alwaysraise LLC and 24,141 shares through Alwaysraise Ventures I, LP. While the company holds more cash than debt, analysts don’t expect profitability this year. Discover 8 more key insights about IMMX with InvestingPro.
In other recent news, Immix Biopharma, Inc. has reported positive interim results from its Phase 1/2 NEXICART-2 clinical trial for NXC-201, a therapy targeting AL Amyloidosis. The trial demonstrated a complete response rate of 71%, with no relapses and a favorable safety profile. These results were presented at the American Society of Clinical Oncology Annual Meeting, highlighting the potential of NXC-201 to address a significant unmet medical need in this patient population. Furthermore, Immix Biopharma has entered into an At The Market Offering Agreement with Citizens JMP Securities, LLC, allowing the company to sell shares of its common stock at its discretion. This agreement is conducted under the company’s existing Registration Statement on Form S-3. Analysts at H.C. Wainwright have reaffirmed their Buy rating for Immix Biopharma stock, citing the promising data from the NEXICART-2 trial as a basis for their positive outlook. The trial is proceeding ahead of schedule, with 14 U.S. sites actively enrolling patients, marking a significant increase in participation. Immix Biopharma plans to submit a Biologics License Application for FDA approval, aiming to make NXC-201 the first approved therapy for AL Amyloidosis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.